Grifols' US arm to sell ADI's colon cancer monitor
This article was originally published in Clinica
AMDL Diagnostics (ADI) has enlisted Grifols, one of Spain's largest and most established healthcare multinationals, as the exclusive distributor of its colorectal cancer test. The five-year agreement will see Grifols USA market the DR-70 Onko-Sure test to hospitals and labs nationwide, for monitoring the recurrence of colorectal cancer. ADI was created in August by its parent company, Tustin, California-based Radient Pharmaceuticals (formerly known as AMDL), to focus exclusively on the commercialisation of Onko-Sure (www.clinica.co.uk, August 21 2009). According to Radient, around 151,000 new cases of colorectal cancer were diagnosed in the US in 2008 – almost half of all patients thought to be cured are expected to develop a recurrence of the cancer within five years, usually due to undetected metastases.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.